Pharmaceutical Investing Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19
Pharmaceutical Investing Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia
Pharmaceutical Investing Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants
Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
Pharmaceutical Investing Algernon Presents “The Science of Ifenprodil” on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD
Pharmaceutical Investing Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea
Pharmaceutical Investing Algernon Submits Application to Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
Pharmaceutical Investing Algernon Receives Positive Feedback from U.S. FDA for New Ifenprodil Intravenous Formulation
Pharmaceutical Investing Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board
Pharmaceutical Investing Algernon Announces Regulatory Submission for Ifenprodil COVID-19 Human Trial in South Korea
Pharmaceutical Investing Algernon Announces Positive Feedback from Health Canada for Ifenprodil COVID-19 Phase 2 Human Trial
Pharmaceutical Investing Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19
Pharmaceutical Investing Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study
Pharmaceutical Investing Algernon Provides an Overview of its NP-120 (Ifenprodil) Program for COVID-19
Skyharbour Partner Company Terra Clean Energy Completes Winter Drill Program with Encouraging Results and Prepares a Significant Summer Drill Program at the South Falcon East Uranium Project
Riverside Resources Moves Ahead on Plan to Spin Out Blue Jay to Shareholders After Approval at the Annual and Special Meeting
